---
document_datetime: 2025-08-25 14:17:52
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/galafold-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: galafold-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.1573284
conversion_datetime: 2025-12-24 19:54:44.897291
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Galafold

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                           |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------|
| Variation type IB /  | C.I HUMAN AND VETERINARY MEDICINAL | 22/08/2025                          |                                             | SmPC,                            | To add an amenable mutation to section 5.1 of the |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000285583   | PRODUCTS - C.I.z Other variation - Accepted To add an amenable mutation to section 5.1 of the SmPC. In addition the MAH took the opportunity to update the contact details of the local representatives in HR and RO and to update the outer packaging to better describe and ensure correct dosing.   | Labelling and PL   | SmPC. In addition, the MAH took the opportunity to update the contact details of the local representatives in HR and RO and to update the outer packaging to better describe and ensure correct dosing.   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|